Celly Nutrition Partners with Leading Investment Bank for Growth
Quantum BioPharma Ltd. (NASDAQ: QNTM) is proud to announce that its licensee, Celly Nutrition Corporation, has taken significant steps in its growth journey. Celly Nutrition, known for its innovative product unbuzzd™, a beverage that accelerates alcohol metabolism and reduces hangover symptoms, has engaged a prominent New York investment bank. This partnership aims to facilitate raising up to $10 million in capital and exploring a possible initial public offering on a major public exchange.
Strategic Objectives for Celly Nutrition
The strategic move to engage an investment bank underscores Celly Nutrition's commitment to scaling its operations and increasing market presence. The investment bank will provide guidance on various matters, including: (a) Advising on potential uplisting to a major U.S. exchange or reverse merger options; (b) Acting as the exclusive managing underwriter for a proposed public offering of Common Stock. This financing will allow Celly Nutrition to enhance its marketing and distribution efforts for unbuzzd™.
The Impact and Vision of unbuzzd™
As a pioneer in the wellness and recovery supplement space, unbuzzd™ is receiving significant attention in the marketplace. This product has undergone rigorous scientific research that highlights its effectiveness in helping the body process alcohol more quickly while restoring mental clarity and reducing alcohol-related fatigue. These aspects make unbuzzd™ appealing to a wide range of consumers looking to enjoy social drinking responsibly.
Recent Clinical Study Outcomes
An impressive double-blind, placebo-controlled clinical study demonstrated unbuzzd™'s efficacy. The study's findings revealed that participants experienced a more than 40% faster reduction in blood alcohol concentration (BAC) within 30 minutes of consuming unbuzzd™. Additionally, unbuzzd™ has shown to improve alertness, stabilize physiological changes during intoxication, and provide significant hangover relief without side effects.
Leadership’s Perspective
John Duffy, CEO of Celly Nutrition, expressed enthusiasm for the future. He noted that this capital raise is not just an opportunity but a milestone that will enable the company to escalate marketing efforts for unbuzzd™. With over two decades of experience in the beverage industry, Duffy's leadership bodes well for Celly Nutrition's future growth.
About Quantum BioPharma Ltd.
Quantum BioPharma is dedicated to developing a diverse range of innovative solutions for treating neurodegenerative disorders and alcohol use issues. The company focuses on bringing groundbreaking products to market and values its strategic investment in Celly Nutrition, where it retains a 25.71% ownership stake. Quantum continues to innovate through its subsidiary, Lucid Psycheceuticals Inc., especially with its lead compound aimed at combating multiple sclerosis.
Innovation for the Future
The partnership between Quantum BioPharma and Celly Nutrition is a forward-thinking strategy aimed at enhancing the accessibility and reach of unbuzzd™. The innovative formulation of unbuzzd™, comprising a proprietary blend of vitamins, minerals, and herbs, continues to attract attention not only from consumers but also from the investor community.
Looking Ahead
As Celly Nutrition explores its public offering, the excitement around unbuzzd™ is growing. The leadership team is eager to tap into the potential of retail investors and capitalize on the product's rising popularity. With a well-established brand and promising clinical outcomes, Celly Nutrition is positioned for success.
Frequently Asked Questions
What is the main purpose of Celly Nutrition engaging the investment bank?
The investment bank will assist Celly Nutrition in raising up to $10 million and advise on potential public offering strategies.
What is unbuzzd™?
unbuzzd™ is a beverage designed to accelerate alcohol metabolism, restore clarity, and reduce hangover symptoms.
How is Quantum BioPharma involved with Celly Nutrition?
Quantum BioPharma retains a 25.71% ownership in Celly Nutrition and emphasizes the importance of innovative solutions in its portfolio.
What were the outcomes of the recent clinical study on unbuzzd™?
The study revealed that unbuzzd™ significantly reduces BAC faster and improves alertness while providing hangover relief without side effects.
What are the potential benefits for investors in Celly Nutrition?
Investors may have an opportunity to participate in the growth of a pioneering company in the wellness sector as it prepares for a public offering.
